<DOC>
	<DOCNO>NCT00280605</DOCNO>
	<brief_summary>The aim study collect , daily practice condition , clinical data safety profile efficacy new formulation alfuzosin administer daily patient low urinary tract symptom ( LUTS ) suggestive benign prostatic hyperplasia ( BPH ) .</brief_summary>
	<brief_title>ALF-ONE : ALFuzosin ONcE Daily</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Ambulatory patient suffer Lower Urinary Tract Symptoms suggestive Benign Prostatic Hyperplasia Patients require Benign Prostatic Hyperplasia surgery immediately within 12 following month Patients previously improve alpha 1blocker treatment Patients whose urinary symptom satisfactorily control Benign Prostatic Hyperplasia medication ( alpha 1blockers 5ARI ) Known hypersensitivity alfuzosin History postural hypotension syncope Combination alpha 1blockers Hepatic insufficiency Unstable angina pectoris Severe concomitant condition threaten life</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>